Company news

Corbus Pharmaceuticals Holdings, Inc. news in 2020

Corbus Pharmaceuticals Holdings, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Corbus Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Updates

November 9, 2020

Corbus Pharmaceuticals to Report Third Quarter Results on November 10, 2020

November 2, 2020

Corbus Pharmaceuticals Announces Presentation of Data from its Phase 2b Study in Cystic Fibrosis at NACFC 2020

October 22, 2020

Corbus Pharmaceuticals Announces Three Lenabasum Abstracts to be Presented at ACR Convergence 2020

October 20, 2020

Corbus Pharmaceuticals Announces Corporate Restructuring and Pipeline Portfolio Updates

October 7, 2020

Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint

October 5, 2020

Corbus Pharmaceuticals Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis

September 7, 2020

Corbus Pharmaceuticals Reports Second Quarter Financial Results and Corporate Updates

August 5, 2020

Corbus Pharmaceuticals Completes Enrollment in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis

August 4, 2020

Corbus Pharmaceuticals Appoints George Golumbeski, Ph.D., to Board of Directors

July 7, 2020

Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis

June 21, 2020

Corbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics in the Journal of Cystic Fibrosis

May 31, 2020

Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis

May 26, 2020

Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress

May 21, 2020

Corbus Pharmaceuticals Reports First Quarter Financial Results and Corporate Updates

May 10, 2020

Corbus Pharmaceuticals to Report First Quarter Results on May 11, 2020

May 3, 2020

Corbus Announces Publication of Lenabasum Systemic Sclerosis Double-Blind, Placebo-Control Phase 2 Clinical Trial Results in Arthritis & Rheumatology

April 28, 2020

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results

March 11, 2020

Corbus Pharmaceuticals Announces Changes to its Board and Appointment of Pete Salzmann, M.D. as Independent Director

March 9, 2020

Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2019 Results on March 12, 2020

March 4, 2020

Corbus Pharmaceuticals Announces Closing of $46 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

February 10, 2020

Corbus Pharmaceuticals Announces Pricing of Public Offering of Common Stock

February 6, 2020

Corbus Pharmaceuticals Announces Proposed Public Offering of Common Stock

February 5, 2020

Calls in 2020

Decks in 2020